Biotech CVR Plays

[Stowe]

Do these have any life left in them or have they run out?

[PENNIEStoSTACKS]

NXGT - OS - 69,479,689 - 09/01/2021 Looking to acquire $100,000,000 + like Businesses, also keep this in mind
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164876945

Nexteligent Opportunity Assessment
Acquisition Growth Strategy:
OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v3 February 2021) Page 12 of 26
• Nexteligent continues to explore acquisition opportunities to expand its product and service offerings and
geographic locations.
• The Company has retained Corporate Finance Associates Worldwide (CFAW) to its support acquisition growth
strategy with target identification, contract negotiations, due diligence, and funding.
• Discovery is currently underway for three signed Letters of Intent (LOIs) that management anticipates closing
before end-of-year 2021.
• Nexteligent is working with CFAW to identify and acquire larger mid-sized companies with a collective revenue
of $100,000,000.
Additional Capital Requirements
• In the near term, Nexteligent expects to begin a period of strategic expansion to fulfill our business objectives
requiring additional capital from new and existing sources.
• We intend to keep our existing and potential stockholders apprised of new business developments by building
and implementing a public relations policy that includes quarterly stockholder communications and brand
building.
• The Company has an agreement in principle with 2 Watchmen, LLC, a Wyoming limited liability company in
formation, to assist the Company in its proposed common stock buy-back program. The Company expects the
proposed program will repurchase from $100,000 to $1,000,000 in Company common stock at market prices.
• The Company has taken preliminary steps to list its common stock on the OTCQX Market, starting with a
detailed audit conducted by a PCAOB accredited accounting firm and a review of the Company’s public
disclosure and corporate structure by legal professionals with substantial public company experience.
• The OTCQX the highest market tier of OTC Markets, requiring PCAOB audited financial statements and filing
with the Securities and Exchange Commission (the “Commission”) as a reporting company under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), with enhanced disclosure requirements
and greater market liquidity.
Organizational Design
• Through its four specialized divisions, the Company delivers services and products that include revenue
cycle management, preventative wellness and chronic care management, telemedicine and healthcare IT,
and consulting services and marketing to healthcare providers spanning hospitals, clinics, doctors, home
healthcare providers, labs, and skilled nursing and assisted living facilities.
• Each company that joins the Nexteligent family maintains its operating structure, management team and
workforce. Nexteligent Corporate works to achieve economies of scale, efficiencies, and cross selling
opportunities.
• Nexteligent’s organizational structure currently includes a Board of Directors that includes Majid Pishyar,
Chairman; Paul Cristiano, Vice Chairman and CEO of Nexteligent Holdings, Inc.; Raymond Pomante,
President and COO Nexteligent Holdings, Inc., and; Amin Pishyar, Outside Director.
• The Company will feature an Operating Committee with senior executives from each operating entity to
address strategic planning, service and product innovation, cross selling, and acquisition identification.

https://backend.otcmarkets.com/otcapi/company/financial-report/299026/content

[makinezmoney]

Sales


Debt

Share Structure


Insider Ownership %



fill me in on the deets

[PENNIEStoSTACKS]

NXGT MEDICAL PLAY - Float - 25,864,090 - 06/30/2021

$NXGT Float - 25,864,090 - 06/30/2021https://t.co/tYBDFURJ1T#Stocks Buy Back Initiativehttps://t.co/KdVrcLRe7U#OTCQX Uplistinghttps://t.co/KdVrcLRe7U#Merger #Acquisitionshttps://t.co/KdVrcLRe7U$MTRT $BBIG $CEI $PHHRF $IBGR $CLNV $RGBP $NSAV $VXIT $LCLP $EEENF $ASTA pic.twitter.com/1a5u6ZUZmF

— PENNIES to STACKS (@PENNIEStoSTACKS) September 1, 2021

Good one for the Radar. Imo

[Magnum7419]

Breakout Boards

Rank Board Rate* Posts Today News Quote** Last Change Chg% Volume ?***
1 Galaxy Next Generation Inc. (GAXY) 1,591% 350 GAXY 0.008 0.0038 90.48% 63,988,549

[Pnypnchr]

Where did everyone go?
LMMFAO

[Chaka]

Okay..
After all the NONSENSE fighting.
I see us going up again..
GILEAD FDA APPROVE?
WE ROCK FOLKS.
$LGND
$LGNDZ

[Richbaby]

Go LGNDZ

[Chaka]

PEOPLE NEEDS TO SEE AND READ AND SEE THE SP WHILE THEY'RE READING THE BOARD.
ALL THEY SEE IS A WHOPPING $77+ TICKER SYMBOL.
SHIT..
THEY'LL JUST SKIP.

[Papa Bear]

That is why I have stopped posting there

[Chaka]

it confuses new playas when they see $77+ pps ticker without any of LGDNZ or any other CVR prices on the main LIGAND board.
Plus all that immature fighting like 12 years old.

[Papa Bear]

Unfortunately

[Chaka]

Just as I thought.
ALL THE FIGHTING AND ALL THE BS..
the tickers tank

[jfkspire]

Vaccine for COVID-19 (TRUMP is gonna Talk about this stock!).$INO.
https://www.msn.com/en-us/health/medical/inovio-pharmaceuticals-plans-first-dosing-of-patients-in-trial-of-dna-covid-19-vaccine-candiate-on-monday/ar-BB12dS1u

$INO

[usma67korea]

cratering..

but did have 2 huge up days

[Papa Bear]

$LGNYZ ~~~~> Big time mover this week!

[Deeznuts]

LGNYZ is a BIG TIME PLAYER THIS WEEK

[Papa Bear]

$LGNDZ ~~~> Big time player this week

[Papa Bear]

$CELGZ

[Papa Bear]

$CRRVF

[Papa Bear]

$GVCRZ

[Papa Bear]

$VLGCR

[Papa Bear]

$BMYRT

[Papa Bear]

Good morning to all

[Papa Bear]

LIGAND PROVIDES A CORPORATE UPDATE AND ANNOUNCES MAY 6TH AS THE DATE FOR FIRST QUARTER EARNINGS CALL

https://investor.ligand.com/press-releases/detail/410/ligand-provides-a-corporate-update-and-announces-may-6th-as

[makinezmoney]

$LGNDZ: Listen to Dr.StableGenius......

And you die.


https://www.forbes.com/sites/tarahaelle/2020/03/23/man-dead-from-taking-chloroquine-after-trump-touts-drug-for-coronavirus/


GO $LGNDZ

[BeamMeUpScotty]

Amazing stuff TY so much for posting. So this is for LGNDZ?

[Papa Bear]

Anytime. If you have any other CVR plays ... please feel free to post. We will see enough LGND posts here over the next few weeks that we are going to need to balance things out here

[decogold]

Yes, got that. Thank you for invite

[Papa Bear]

Thats good .... the way this board is set up is that we can post about all biotech cvr's equally but the board CANNOT be a 100% substitute for the LGND board. If all posts are about LGND and LGND* constantly .... admin WILL shut this board down.

[decogold]

Yes,LGNDZ$$$_$$$$$. I like that then we don't have to deal with the puppet popping off its mouth every second.

[Papa Bear]

$VLGCR

[Papa Bear]

$BMYRT

[Papa Bear]

BINGO! Golden ticket plays ~~> $LGND*

[19Neener]

Here's the connection: GILD's COVID-19's drug Remdesivir needs LGND's drug Captisol to work.

[Papa Bear]

Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab


https://www.biospace.com/article/releases/mereo-biopharma-announces-update-on-distribution-related-to-contingent-value-rights-following-recent-oncologie-licensing-agreement-for-navicixizumab/

[Papa Bear]

An All-or-Nothing Bet on 3 Drugs in Celgene’s Pipeline

https://www.barrons.com/articles/with-bristol-myers-cvr-investors-can-bet-on-3-drugs-in-celgenes-pipeline-51574269284

[Papa Bear]

Correct and the quietness on LGND is about to end. Think about it .... GILD gets positive FDA news .... LGND has the ingredient that makes GILD CV19 vaccine work ... someone is going to look at LGND as a buy out option. One step at a time but it is coming ... keep an eye out for FDA news :)

[usma67korea]

yes i am aware. biggest frustration of LGND reg. shares have been just that... mkt seems to be asleep on LGND (vs GILD which is getting the attention, rightfully so). LGND is so undervalued..

GILD will prob be > $100 once CV drug is 'approved' - how can they NOT approve imo.... for many reasons.

[Papa Bear]

Also ... we are on GILD news watch from the FDA

[Papa Bear]

These cvr's have been undervalued for a long time. They are now moving forward. Really ... in a perfect world .... these cvr's should reflect about 10% of the parent stock. We shall soon see .... the opening for all cvr's should be huge.

[usma67korea]

thanks for the postings. appreciate it man.

still not sure what would be driving this 10X + increase just in a few days with few of these CVs associated with LGND.

I mean I hold LGND for many years and I do know they are 'supporting' GILD's Coronavirus drug (potentially) but the regular shares have been stagnant at best.. yet these CVs are rocketing higher. I just don't get the link

[Randylus]

If you are viewing this on mobile, it may be all run together without paragraph formatting. Best to view on a desktop or laptop where the formatting is correct. Good luck to all - feed back encouraged. randy

[Randylus]

The following are the CONTINGENT VALUE RIGHTS Agreements and links to SEC Filings for;

Ligand pharmaceuticals Inc. (LGND) Nasdaq - FORM 8-K January 27, 2010
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/d8k.htm

There is an individual SEC filing for each CRV below as well.

LGNDZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex101.htm

Roche Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010

Roche CVR. The Roche CVR Agreement entitles each holder of a Roche CVR to receive a pro rata portion of 65% of any milestone payments or 68% of any royalties paid by Roche under Metabasis’ partnered drug development program with Roche in hepatitis C, or 65% of the net proceeds of any sale of those program rights.

=================

The following are CRV's from the Acquisition of Metabasis Therapeutics, Inc. on January 28, 2010

News Release on the Merger Completion of ligand and Metabasis Therapeutics, Inc.,: https://www.businesswire.com/news/home/20100128005321/en/Ligand-Completes-Acquisition-Metabasis

https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/0001193125-10-015242-index.htm

LGNZZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm

TR Beta Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010

TR Beta CVR. The TR Beta CVR Agreement entitles each holder of a TR Beta CVR to receive a pro rata portion of a percentage of the net proceeds of any license or sale of Metabasis’ Thyroid Receptor Beta program in hyperlipidemia: 50% of such net proceeds if the licensing/sale transaction occurs by the sixth anniversary of the Merger; 40% if in the seventh year after the Merger; 30% if in the eighth year after the Merger; or 20% if in the ninth or tenth year after the Merger.


LGNXZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex103.htm

Glucagon Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010

Glucagon CVR. The Glucagon CVR Agreement entitles each holder of a Glucagon CVR to receive a pro rata portion of a percentage of the net proceeds of any license or sale of Metabasis’ glucagon receptor antagonist program in diabetes: 50% of such net proceeds if the licensing/sale transaction occurs by the sixth anniversary of the Merger; 40% if in the seventh year after the Merger; 30% if in the eighth year after the Merger; or 20% if in the ninth or tenth year after the Merger.

https://www.businesswire.com/news/home/20100128005321/en/Ligand-Completes-Acquisition-Metabasis

LGNYZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm

General Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010

General CVR. The General CVR Agreement entitles each holder of a General CVR to receive a pro rata portion of cash payments equal to the shortfall, if any, from defined spending thresholds of Ligand’s funding of further research and development of drug development programs acquired from Metabasis. The basic threshold is $8 million of funding within the first 42 months after the Merger. A secondary threshold (which shall be waived in certain circumstances) is $7 million of funding within the first 30 months after the Merger.

[Papa Bear]

Good afternoon .... I am in the middle of doing a few things now but I will answer your question a little later if no one else does by then

[usma67korea]

guys, sorry i am novice here, but why have these LGND OTC plays have gone up few hundred % last 2 days. what's driving them? any quick 1-2 line replies are welcome. i have LGND in my regular shares and been a fan for long time but never looked at these warrant plays

[Thehustle]

Ok.. So I’ll stick to the main focus here. Will look for more good ones

[Papa Bear]

We can throw a non CVR bio in here from time to time

[Thehustle]

PB Are bios plays that don’t have CVRs allowed to be talked about?

[Papa Bear]

Greetings my friend. Gotta love new trends!